Equity Overview
Price & Market Data
Price: $0.0₅1
Daily Change: $0.00 / 0.00%
Range: $0.0₅1 - $0.0₅1
Market Cap: $3,496
Volume: 1,016
Performance Metrics
1 Week: 9,900%
1 Month: 9,900%
3 Months: %
6 Months: %
1 Year: -99.98%
YTD: %
Company Details
Employees: 208
Sector: Health technology
Industry: Medical specialties
Country: United States
Details
DermTech, Inc., a molecular diagnostic company, engages in the development and marketing of novel non-invasive genomics tests to aid in the diagnosis and management of melanoma in the United States. The company provides DermTech Melanoma Test (DMT), an innovative non-invasive way to enhance melanoma detection for developing product for non-melanoma skin cancers. It also offers DermTech Smart Sticker, which provides a non-invasively way to collect skin sample including standard care by using scalpel to biopsy suspicious lesions. In addition, it provides research services and technology platform on a contract basis to pharmaceutical companies which use the technology for clinical trials. Further, the company develops gene expression assays for the psoriasis, atopic dermatitis, and aging of the skin to pharmaceutical companies to develop drug products in dermatology; and develop custom gene assays to support the pharmaceutical partners. It sells its products through pathology and oncology practitioners. DermTech, Inc. is headquartered in San Diego, California. On June 18, 2024, DermTech, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.